- |||||||||| Lipotecan (TLC388) / Taiwan Liposome Company
Journal, Combination therapy: Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy. (Pubmed Central) - Apr 6, 2024 The infiltration of cytotoxic T and NK cells were more profoundly existed within tumors in combination with radiotherapy and ICIs, leading to superior therapeutic efficacy in poorly immunogenic MSS-CRC. Taken together, these results showed that the novel topoisomerase I inhibitor TLC388 increased cancer immunogenicity by ssDNA/STING-mediated IFN-I production, enhancing antitumor immunity for better therapeutic efficacy in combination with radiotherapy and ICIs for poorly immunogenic cancer.
- |||||||||| Lipotecan (TLC388) / Taiwan Liposome Company
Clinical, Journal, Immunogenic cell death: Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy. (Pubmed Central) - Apr 7, 2021 Lipotecan thereby increases cancer immunogenicity and triggers an antitumor immune response to attract immune cell infiltration within the tumor microenvironment (TME) in vitro and in vivo. Taken together, these results show that lipotecan can remodel the tumor microenvironment to provoke anticancer immune responses, which can provide potential clinical benefits to the therapeutic efficacy of neoCRT in LARC patients.
- |||||||||| Lipotecan (TLC388) / Taiwan Liposome Company
Trial termination, Metastases: Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 26, 2019 P2, N=29, Terminated, Not yet recruiting --> Completed | N=44 --> 23 | Trial completion date: Dec 2020 --> Dec 2018 | Trial primary completion date: Dec 2018 --> Apr 2018 Completed --> Terminated; Current study design couldn't support futher development on this indication
- |||||||||| Lipotecan (TLC388) / Taiwan Liposome Company
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (clinicaltrials.gov) - Nov 6, 2018 P1/2, N=1, Terminated, Completed --> Terminated; Current study design couldn't support futher development on this indication N=40 --> 1 | Trial completion date: Sep 2020 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2020 --> Oct 2018; Current study design couldn't support futher development on this indication.
- |||||||||| Lipotecan (TLC388) / Taiwan Liposome Company
Enrollment change, Metastases: A Dose-escalation Study of Lipotecan (clinicaltrials.gov) - Jun 27, 2018 P1/2, N=3, Terminated, N=40 --> 1 | Trial completion date: Sep 2020 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2020 --> Oct 2018; Current study design couldn't support futher development on this indication. N=60 --> 3
- |||||||||| Lipotecan (TLC388) / Taiwan Liposome Company
Trial completion, Metastases: Phase I Study of Intravenous Lipotecan (clinicaltrials.gov) - Feb 7, 2012 P1, N=54, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Lipotecan (TLC388) / Taiwan Liposome Company
Enrollment change, Metastases: Phase I Study of Intravenous Lipotecan (clinicaltrials.gov) - Sep 25, 2011 P1, N=54, Completed, Active, not recruiting --> Completed N=40 --> 54
|